Biotech News

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

Scholar Rock (SRRK)Scholar Rock2026-04-16 12:00 ESTEarnings

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 16, 2026-- Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at

Scholar Rock

Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways. Apitegromab Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal...

Recent company news

SRRKScholar Rock2026-08-14 20:15 EST

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRRKScholar Rock2026-08-07 20:20 EST

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

SRRKScholar Rock2026-08-06 11:00 EST

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

SRRKScholar Rock2026-07-29 12:00 EST

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

SRRKScholar Rock2026-07-20 12:00 EST

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Stock data

Close: 52.05 USD
Market cap: 5.35B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States